Description
Description
This page contains brief details about the drug bortezomib, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
Bortezomib is a first-generation proteasome inhibitor which was approved for its medical use on 13th May 2003.
Mechanism of Action of Bortezomib
Bortezomib is an anticancer medication that belongs to the category of medicines called proteasome inhibitors. it disrupts signalling cascades, interferes with transcription and promotes DNA damage, ultimately inducing programmed cell death to stop the growth and spread of cancer cells. Bortezomib is used in combination with other treatment like cyclophosphamide, doxorubicin, prednisone or rituximab.
Uses of Bortezomib
Bortezomib has been developed to treat adult patients diagnosed with Multiple myeloma and mantle cell lymphoma.
Bortezomib Dosage available
Bortezomib is available in the form of single dose vial containing lyophilized powder for injection in the doses 1mg, 2mg, 2.5mg, 3.5mg. Bortezomib Injection is intended for administration through intravenous and subcutaneous route only. Your healthcare provider will calculate the accurate dose depending on your health condition and the route of administration.
